On This Day in Health: September 14, 1990
On September 14, 1990, clinicians at the National Institutes of Health began the first approved human gene-therapy treatment in the United States. The patient was four-year-old Ashanthi DeSilva, who had the inherited immune disorder ADA-SCID.
Researchers removed T cells, used a modified retrovirus to add a functioning ADA gene, and returned the cells to the patient. The experimental procedure supplemented existing treatment and required careful regulatory review and follow-up.
Gene therapy has since expanded to inherited disorders and some cancers using newer vectors and gene-editing methods. The 1990 case remains a milestone because it moved gene transfer from laboratory research into an approved clinical protocol.
ADA-SCID disrupts immune function by preventing the body from producing enough working adenosine deaminase enzyme.
The ex vivo approach allowed researchers to modify and examine cells before returning them to the patient.
The procedure demonstrated that approved human gene transfer was possible, but it was not a universal or immediate cure.
The patient continued receiving other care, and the modified T cells did not permanently replace every affected cell.
The case helped establish expectations for consent, oversight, manufacturing controls, and long-term monitoring.
Source: NIH Clinical Center.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.